Business Description
Viatris Inc
NAICS : 325411
SIC : 2833
ISIN : US92556V1061
Total Employee Number:
30,000Compare
Compare
Traded in other countries / regions
VTRS.USA0A5V.UKVIA.GermanyMYL.Austria1VTRS.ItalyMYL.MexicoVTRS.Switzerland Index Membership
S&P 500Russell 1000Russell 3000NASDAQ 100 IPO Date
1973-02-23Description
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.07 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-Equity | 0.94 | |||||
Debt-to-EBITDA | 10.49 | |||||
Interest Coverage | 0.27 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.06 | |||||
Beneish M-Score | -2.91 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.9 | |||||
3-Year EPS without NRI Growth Rate | -11.1 | |||||
3-Year FCF Growth Rate | -8.5 | |||||
3-Year Book Growth Rate | -9.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.32 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.81 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.6 | |||||
9-Day RSI | 42.92 | |||||
14-Day RSI | 44.96 | |||||
3-1 Month Momentum % | 10.86 | |||||
6-1 Month Momentum % | 19.62 | |||||
12-1 Month Momentum % | 71.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.58 | |||||
Quick Ratio | 0.96 | |||||
Cash Ratio | 0.14 | |||||
Days Inventory | 153.8 | |||||
Days Sales Outstanding | 71.76 | |||||
Days Payable | 48.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.94 | |||||
Dividend Payout Ratio | 0.19 | |||||
Forward Dividend Yield % | 2.94 | |||||
5-Year Yield-on-Cost % | 2.94 | |||||
3-Year Average Share Buyback Ratio | 1.7 | |||||
Shareholder Yield % | 7.76 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 34.83 | |||||
Operating Margin % | 0.89 | |||||
Net Margin % | -2.79 | |||||
EBITDA Margin % | 8.64 | |||||
FCF Margin % | 12.3 | |||||
OCF Margin % | 15.82 | |||||
ROE % | -2.76 | |||||
ROA % | -1.11 | |||||
ROIC % | 0.25 | |||||
3-Year ROIIC % | 7.68 | |||||
ROC (Joel Greenblatt) % | -2.93 | |||||
ROCE % | -0.6 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 6.52 | |||||
PE Ratio without NRI | 6.49 | |||||
Price-to-Owner-Earnings | 23.03 | |||||
PS Ratio | 1.29 | |||||
PB Ratio | 1.32 | |||||
Price-to-Free-Cash-Flow | 10.48 | |||||
Price-to-Operating-Cash-Flow | 8.15 | |||||
EV-to-EBIT | -169.57 | |||||
EV-to-Forward-EBIT | 149.98 | |||||
EV-to-EBITDA | 24.27 | |||||
EV-to-Forward-EBITDA | 10.67 | |||||
EV-to-Revenue | 2.1 | |||||
EV-to-Forward-Revenue | 2.09 | |||||
EV-to-FCF | 17.05 | |||||
Price-to-GF-Value | 1.43 | |||||
Price-to-Projected-FCF | 0.64 | |||||
Price-to-Median-PS-Value | 1.46 | |||||
Earnings Yield (Greenblatt) % | -0.59 | |||||
FCF Yield % | 9.65 | |||||
Forward Rate of Return (Yacktman) % | -0.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VTRS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viatris Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14,737.3 | ||
| EPS (TTM) ($) | -0.36 | ||
| Beta | 0.9691 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 0.98 | ||
| Volatility % | 31.71 | ||
| 14-Day RSI | 44.96 | ||
| 14-Day ATR ($) | 0.464251 | ||
| 20-Day SMA ($) | 16.55425 | ||
| 12-1 Month Momentum % | 71.57 | ||
| 52-Week Range ($) | 9.425 - 18.39 | ||
| Shares Outstanding (Mil) | 1,148.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Viatris Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Viatris Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 08:30 | In 180 days | ||
| Annual report for 2026 | 2027-02-26 | In 179 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 179 days | ||
| General meeting for 2026 | 2026-12-04 11:00 | In 96 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 68 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 67 days | ||
| USD 0.120000 Cash Dividend | 2026-08-21 | 16.12 (+0.32%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:30 | 17.65 (-0.84%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 17.65 (-0.84%) | ||
| USD 0.120000 Cash Dividend | 2026-05-22 | 16.46 (-0.36%) |
Show
Entries
Viatris Inc Frequently Asked Questions
What is Viatris Inc(VTRS)'s stock price today?
The current price of VTRS is $16.35. The 52 week high of VTRS is $18.39 and 52 week low is $9.43.
When is next earnings date of Viatris Inc(VTRS)?
The next earnings date of Viatris Inc(VTRS) is 2026-11-06 Est..
Does Viatris Inc(VTRS) pay dividends? If so, how much?
The Dividend Yield %  of Viatris Inc(VTRS) is 2.94% (As of Today), Highest Dividend Payout Ratio of Viatris Inc(VTRS) was 0.2. The lowest was 0.14. And the median was 0.17. The  Forward Dividend Yield % of Viatris Inc(VTRS) is 2.94%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NAS:VTRS
Summers Value Fund
Bullish
2026 Q1
What the manager wrote
Viatris is positioned for growth through its partnership with Theravance, particularly with the Yupelri product for COPD. The company reported 12% sales growth for Yupelri in 2025, and we anticipate continued growth driven by increased U.S. hospital adoption and the upcoming launch in China. With patent protection extending through April 2039, Yupelri represents a long-duration and growing cash flow stream. We value the U.S. business at $520 million and the China opportunity at $200 million, supported by Viatris' extensive sales force of over 4,000 reps, which should facilitate a successful launch.
Press Release
Articles on Viatris Inc
Chris Davis's Top Q2 2026 Move: Exiting Coterra Energy Inc at a -5.99% Portfolio Impact
Aug 11, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers